Abstract:Breast cancer is the most frequently diagnosed cancer and the leading cause of mortality in females worldwide. Despite the great improvement in survival rates the last two decades, relapsed disease with metastasis still remains the most poorly understood aspect of cancer pathogenesis [1]. Consequently, there is a growing need to identify so-called new ‘players’ implicated in this process. Lemur tyrosine kinase 3 (LMTK3), a member of the receptor tyrosine kinase (RTK) family, has been previously identified as a central protein involved in breast cancer growth and endocrine resistance and it has also been subjected to Darwinian positive selection as described [2-5]. Moreover, increased LMTK3 expression associates with poor overall and disease-free survival, indicative of a potential involvement of LMTK3 in breast cancer progression. Cell migration and invasion are the early steps of the metastatic process controlled by cellular signals that stimulate changes in cell adhesion and cytoskeleton formation [6]. We have now reported that LMTK3 is highly expressed in triple negative breast cancers and it is implicated in actin cytoskeleton remodeling, focal adhesion formation and increased cell motility [7]. In vitro experiments showed that overexpression of LMTK3 accelerates the dispersion and invasion of breast cancer cells towards the matrigel and collagen, while it increases actin protrusions and focal adhesion formations on the edge of migrating cells. To address the underlying molecular mechanisms, a stable isotope labeling by amino acids in cell culture (SILAC)-based proteomics analysis was implemented to investigate the downstream components of LMTK3-regulated cascade. Interestingly, integrin subunits α5 (ITGA5) and β1 (ITGB1), central receptors in metastatic signal relay, were positively regulated by LMTK3, while high LMTK3 levels were also correlated with increased ITGB1 expression in breast cancer patient samples. In support of the role of LMTK3 in metastatic progression, a proof-of-concept in vivo metastatic mouse model was generated, after injecting parental T47D breast cancer cells and T47D cells overexpressing LMTK3 into the mammary fat pads of female NOD/SCID mice. Our preliminary results revealed that only the T47D-LMTK3 mice developed metastasis in the mammary fat pad after 7 weeks, suggesting the contribution of LMTK3 in metastatic potential (unpublished data). Similar to other RTKs, LMTK3 can directly interact with the adaptor protein GRB2, activate RAS-GTPase family members subsequently leading to upregulated serum response factor (SRF) activity, resulting in increased ITGA5 and ITGB1 gene transcription. A set of gain- and loss-of-function experiments showed that LMTK3 could stimulate SRF indirectly through its action on cell division control protein 42 homolog (CDC42). However, other alternative mechanisms merit investigation, including the possibility that LMTK3 might activate SRF through direct phosphorylation. In support of this hypothesis, in silico analysis revealed potential phosphorylation sites of SRF targeted by LMTK3 that are currently under examination. Moreover, the topology of LMTK3 (cytoplasmic, nuclear and to a lesser degree in the cell membrane), implies that LMTK3 may be capable of shuttling between subcellular compartments upon specific stimuli (i.e. posttranslational modifications) and other cellular conditions. Therefore, understanding the exact role(s) of LMTK3 in different cellular compartments is imperative. In order to characterize substrates phosphorylated by LMTK3, a high-throughput in vitro kinase assay screen is in progress that will further help us uncover the signaling pathways that LMTK3 is implicated in and decipher its contribution in disease. Furthermore, elucidating the upstream mechanisms of LMTK3-regulation is also essential. Till now, there have been no studies regarding the existence of any LMTK3-specific ligand(s) or other proteins (i.e. kinases, phosphatases, etc.) that can directly activate/inactivate the catalytic activity of LMTK3. Unraveling the upstream signaling and cross-talk pathways of LMTK3 would greatly improve our understanding of the underlying mechanisms that contribute to the regulation of LMTK3 and its involvement in invasion and metastasis (Fig (Fig11). Fig 1 Proposed model of LMTK3 action in cancer metastasis In aggregate, based on our results so far, LMTK3 appears to be a promising new target against breast cancer progression and metastasis. Additional work is required to broaden our knowledge of LMTK3 functions at molecular and cellular levels. In parallel, a drug screening program will facilitate the identification of specific LMTK3 inhibitors, which could eventually aid to tackle breast cancer metastasis and endocrine resistance.

Lemur tail kinase 3 serves as a predictor of patient outcomes and a target for the treatment of ovarian cancer

STAT3 Polymorphisms May Predict an Unfavorable Response to First‐line Platinum‐based Therapy for Women with Advanced Serous Epithelial Ovarian Cancer

LMTK3 gene expression and the molecular landscape of colorectal cancer (CRC).

Prognostic Role of Lemur Tyrosine Kinase 3 in Postoperative Gastric Cancer

Lemur Tyrosine Kinase-3 is a Significant Prognostic Marker for Patients with Colorectal Cancer.

Abstract 6832: Gender specific role of LMTK3 in neuronal-tumor microenvironment crosstalk in CRC

MAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas

Serum Lemur Tyrosine Kinase 3 Expression in Colorectal Cancer Patients Predicts Cancer Progression and Prognosis.

Transducin-Like Enhancer of Split 3 (TLE3) expression is associated with taxane sensitivity in non-serous ovarian carcinoma in a three-cohort study.

TLE3 Expression is Associated with Sensitivity to Taxane Treatment in Ovarian Carcinoma.

Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs

Identification of telomere-related lncRNAs and immunological analysis in ovarian cancer

Data from TLE3 Expression is Associated with Sensitivity to Taxane Treatment in Ovarian Carcinoma

Targeting Lemurs Against Cancer Metastasis

Targeting eukaryotic elongation factor-2 kinase suppresses the growth and peritoneal metastasis of ovarian cancer

[Clinical Significance of Targeting Drug-Based Molecular Biomarkers Expression in Ovarian Clear Cell Carcinoma].

Platelet-derived Growth Factor Receptor Alpha (pdgfrα) Targeting and Relevant Biomarkers in Ovarian Carcinoma.

Identification of Lymphatic Metastasis-Associated Genes in a Metastatic Ovarian Cancer Cell Line

The Integrated Bioinformatic Approach Reveals the Prognostic Significance of LRP1 Expression in Ovarian Cancer

TLE3 as a candidate biomarker of response to taxane therapy

Knockdown of LMTK3 in the Endometrioid Adenocarcinoma Cell Line Ishikawa: Inhibition of Growth and Estrogen Receptor α